PerZeption and Alcon Unveil Tech to Revolutionize Vision Testing

BOSTON, MA – May 01, 2026 – The familiar eye chart, a staple of ophthalmology for over a century, may soon be complemented by a far more sophisticated and efficient tool. Boston-based startup PerZeption Inc., in a significant collaboration with eye care leader Alcon Research, is poised to introduce a technology that could fundamentally change how visual performance is measured. The company announced it will present validating data for its AIM+ CSF modeling technology at the upcoming Association of Research in Vision and Ophthalmology (ARVO) annual meeting.

This new approach promises a rapid, highly sensitive, and repeatable assessment of contrast vision, a critical aspect of sight that impacts real-world activities like driving at night or recognizing faces in low light. The joint effort, pairing PerZeption's nimble innovation with Alcon's global research prowess, signals a potential paradigm shift toward more precise, data-driven, and patient-friendly diagnostics in eye care.

A New Lens on Vision Assessment

For decades, the gold standard for measuring contrast sensitivity has often involved cumbersome charts like the Pelli-Robson, which, despite its utility, has practical limitations in a busy clinical setting. PerZeption's technology aims to leapfrog these traditional methods. Its platform, known as Angular Indication Measurement (AIM), utilizes cloud-based software on standard tablets or computers to conduct complex psychophysical tests.

The upcoming ARVO presentation will focus on the AIM+ CSF modeling technology. CSF, or Contrast Sensitivity Function, provides a comprehensive map of a person's vision, detailing how well they perceive contrast across a range of different spatial frequencies. It offers a much richer picture of visual function than a simple acuity test, which only measures sight at high contrast. The key metric highlighted is the AULCSF (Area Under the Log Contrast Sensitivity Function), a single number that summarizes a person's overall spatial vision.

According to the company, the technology is sensitive enough to detect a 1 JND, or "Just Noticeable Difference"—the smallest change in visual stimulus a person can perceive. This level of precision is critical for tracking subtle changes in vision caused by disease progression or for evaluating the effectiveness of new treatments and corrective lenses. The research to be presented indicates that this can be achieved with high statistical power (90%) in a study with as few as 20 subjects. Perhaps most impressively, the entire assessment demonstrates stable repeatability in under three minutes, a fraction of the time required by older methods.

"The results, presented by Dr Derek Nankivil, indicate that our technology enables rapid, repeatable, and highly sensitive assessment of contrast vision," said Dr. Jan Skerswetat, CEO of PerZeption, in a statement.

The Alcon Alliance: A Strategic Vision

The collaboration with Alcon is more than just a research partnership; it is a powerful endorsement from one of the largest and most influential companies in the global ophthalmology sector. For a startup like PerZeption, this alliance provides immense credibility and a potential pathway to accelerated market adoption.

Alcon, which invests approximately $1 billion annually in R&D, has a stated strategy of embracing digital innovation to enhance clinical efficiency and patient outcomes. The company is already rolling out its Unity platform, a cloud-based diagnostic system designed to streamline the workflow for cataract surgery. PerZeption's technology—with its emphasis on cloud delivery, data integration, and efficiency—aligns perfectly with this forward-looking strategy. The partnership suggests Alcon is betting on advanced, software-driven diagnostics as a key component of future eye care ecosystems.

"We are very excited to collaborate with Alcon, one of the largest companies within the Ophthalmology sector worldwide," Dr. Skerswetat noted, highlighting the strategic importance of the relationship. This move could allow Alcon to integrate cutting-edge contrast vision testing into its existing and future product lines, from pre-surgical planning to post-operative assessment, further solidifying its market leadership.

Beyond the Doctor's Office: Democratizing Eye Care

One of the most transformative aspects of PerZeption's platform is its potential to democratize access to advanced vision testing. By running on standard, off-the-shelf hardware and leveraging a cloud-based, self-administered interface, the technology breaks free from the constraints of the traditional clinic.

This opens up profound possibilities for telehealth and remote patient monitoring. Patients in rural or underserved areas, who may lack access to specialized ophthalmic centers, could perform sophisticated visual function tests from a local clinic or even their own homes. This not only enhances convenience but also enables more frequent monitoring of chronic conditions like glaucoma, diabetic retinopathy, or macular degeneration, allowing for earlier intervention.

Furthermore, the platform offers a powerful tool for pharmaceutical companies and researchers. The ability to conduct rapid, repeatable, and standardized tests remotely can dramatically streamline data collection for clinical trials, making them more efficient and cost-effective. The system's capacity to test over 20 different visual functions on a single device replaces the need for multiple, bulky, and specialized single-use machines, addressing the critical issue of 'chairtime' and clinic space.

A Critical Test at ARVO

The ARVO annual meeting is the world's premier event for vision science, making it the ideal stage for PerZeption and Alcon to showcase their work. The presentation, scheduled for May 4, 2026, will be a crucial step in the technology's journey from a research concept to a validated clinical tool. A positive reception from the thousands of ophthalmologists, optometrists, and vision scientists in attendance could catalyze widespread interest.

While the technology's promise is significant, the path to broad adoption involves clearing several hurdles, including navigating the complex regulatory approval processes of bodies like the FDA and securing integration into established clinical workflows and reimbursement systems. Continued validation through independent, peer-reviewed studies will be essential to building the trust necessary for it to become a new standard of care.

In addition to the scientific poster, PerZeption plans to offer hands-on demonstrations at its booth. "We are also proud to be showcasing PerZeption's battery of functional tests at our booth, #4027," Dr. Skerswetat added, noting that there will be opportunities for attendees to try the technology firsthand. For the global vision science community gathering for the event, the data presented at posterboard #0941 may offer the first clear look at the future of eye care.